Canaccord Genuity Reiterates Buy Rating for Jazz Pharmaceuticals plc
's stock had its "buy" rating restated by Canaccord Genuity in a research note issued on Thursday, Stock Ratings Network reports.
Trending on the Topix Network
Fri Apr 11, 2014
Clinical Trial Results and Initiation, Endowment, Product Launches,...
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. , Questcor Pharmaceuticals, Inc. , Jazz Pharmaceuticals plc , Ariad Pharmaceuticals, Inc. , and BioMarin Pharmaceutical Inc. .
Thu Apr 10, 2014
Jazz Pharmaceuticals plc CEO Unloads $615,900 in Stock
Jazz Pharmaceuticals plc CEO Bruce C. Cozadd unloaded 5,000 shares of the stock on the open market in a transaction dated Tuesday, April 8th.
Wed Apr 09, 2014
Jazz Pharma: Risk 1% Downside, 34% Upside To Fair Value
Last year was a year in which the Biotech industry could do no wrong in the eyes of the retail and institutional investor communities.
Tue Apr 08, 2014
Atara Biotherapeutics Bolsters Board, Executives
Thousand Oaks-based drug development company Atara Biotherapeutics announced this morning that it has added Matthew K. Fust as a board member, and hired Mitchall G. Clark as its Chief Regulatory and Quality Assurance Officer.
Thu Apr 03, 2014
Jazz Pharmaceuticals plc Receives Consensus Rating of "Buy" from Brokerages
Jazz Pharmaceuticals plc has been given an average recommendation of "Buy" by the seventeen brokerages that are currently covering the company, Stock Ratings Network reports .
Wed Apr 02, 2014
The Motley Fool
Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic?
The article states that Jazz may be willing to pay north of $20 per share for Ariad and its leukemia drug Iclusig.
Medical News Today
European commercial launch of first approved life-saving treatment...
Jazz Pharmaceuticals plc and Gentium S.p.A., a Jazz Pharmaceuticals company, have announced the commencement of the European commercial launch of Defitelioq , the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy. The ... (more)
Mon Mar 31, 2014
Concert Pharmaceuticals Reports Year End 2013 Financial Results
Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.
Jazz Pharmaceuticals, Gentium Announce European Commercial Launch of Defitelio
Jazz Pharmaceuticals plc and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of DefitelioA ^a-1 4 , the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.
Fri Mar 28, 2014
Option Clips: Ariad Pharmaceuticals, MannKind, and Kroger
StockTwits today are oncology concern Ariad Pharmaceuticals, Inc. and biopharmaceutical issue MannKind Corporation .
Jazz Pharmaceuticals plc Trading Down 3.5% After Analyst Downgrade
Jazz Pharmaceuticals plc 's share price dropped 3.5% during mid-day trading on Friday after Leerink Swann lowered their price target on the stock from $189.00 to $170.00, StockRatingsNetwork.com reports.
Jazz Pharmaceuticals plc Price Target Cut to $170.00
Leerink Swann's price objective would indicate a potential upside of 23.19% from the stock's previous close.
The Motley Fool
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Thu Mar 27, 2014
Market Report: Drug giants fail to swallow Ariad Pharmaceuticals
As shares of UK pharmaceutical giants GlaxoSmithKline shed 9.5p to 1,614p and Shire declined 20p to 3,035p, dealers heard that both had lost out in the auction for Massachusetts-based Ariad Pharmaceuticals.
Fri Mar 21, 2014
Entrepreneur Cashes In $86 Million Of Jazz Pharmaceuticals plc To Fund New Venture
Entrepreneur Seamus Mulligan has cashed in shares worth $86 million in Jazz Pharmaceuticals which will entirely be used to fund a new business called Adapt Pharma.